In a landmark reversal, the National Institute for Health and Care Excellence has approved Enhertu for routine NHS use in England. The drug, previously deemed not cost-effective, will now be accessible to around 1,000 women annually. These patients have HER2-low metastatic breast cancer, a condition that had limited targeted treatment options. Seldom has a pharmaceutical dispute generated such sustained public outcry and institutional scrutiny.
Enhertu is an antibody-drug conjugate, a sophisticated form of targeted therapy developed by AstraZeneca and Daiichi Sankyo. Clinical trials demonstrated that it nearly doubled median progression-free survival compared with conventional chemotherapy. Patients receiving Enhertu survived a median of 23.4 months, versus 16.8 months for those on standard treatment. This 6.6-month gain, while seemingly modest, represents a clinically meaningful extension for those with incurable disease.
The protracted negotiations between NICE, NHS England, and the pharmaceutical manufacturers collapsed three times during 2024. Scotland, which operates an independent health policy framework, had approved the drug considerably earlier. England consequently became one of the final European nations to provide public access. Some women resorted to paying privately, spending approximately 118,000 pounds for a full course of treatment.
A pivotal factor in resolving the deadlock was the government's decision to raise NICE's cost-effectiveness threshold. In April, the maximum permissible expenditure increased to 35,000 pounds per quality-adjusted life year gained. This recalibration, combined with renewed commercial negotiations, ultimately rendered the drug's pricing acceptable. Nevertheless, campaigners emphasised that many patients had tragically died while awaiting this resolution.
The Enhertu case illuminates a broader ethical dilemma confronting publicly funded healthcare systems worldwide. Finite resources necessitate difficult prioritisation decisions, yet such constraints inevitably generate inequitable outcomes. Had the threshold been adjusted sooner, numerous lives might have been prolonged. This episode compels policymakers to re-examine how swiftly innovative treatments can be integrated into national formularies.
